Autolus Therapeutics (NASDAQ:AUTL) Trading Up 8.3%

Autolus Therapeutics plc (NASDAQ:AUTL) was up 8.3% during trading on Wednesday . The stock traded as high as $3.90 and last traded at $3.90. Approximately 755,747 shares changed hands during trading, a decline of 45% from the average daily volume of 1,378,435 shares. The stock had previously closed at $3.60.

Analysts Set New Price Targets

Separately, Needham & Company LLC reissued a “buy” rating and set a $9.00 target price on shares of Autolus Therapeutics in a research note on Monday, June 17th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $8.70.

Autolus Therapeutics Price Performance

The company has a 50 day moving average price of $3.97 and a 200-day moving average price of $4.29. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09. The company has a market cap of $1.06 billion, a price-to-earnings ratio of -3.25 and a beta of 2.05.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). As a group, equities research analysts predict that Autolus Therapeutics plc will post -0.84 EPS for the current fiscal year.

Institutional Trading of Autolus Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Avoro Capital Advisors LLC bought a new position in shares of Autolus Therapeutics during the 1st quarter worth approximately $78,765,000. Armistice Capital LLC raised its position in shares of Autolus Therapeutics by 33.8% during the second quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock worth $21,750,000 after purchasing an additional 1,578,000 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Autolus Therapeutics by 82.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock worth $35,020,000 after purchasing an additional 2,487,778 shares during the period. Affinity Asset Advisors LLC raised its position in shares of Autolus Therapeutics by 27.4% during the second quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock worth $14,964,000 after purchasing an additional 925,000 shares during the period. Finally, Great Point Partners LLC raised its position in shares of Autolus Therapeutics by 195.0% during the second quarter. Great Point Partners LLC now owns 3,441,667 shares of the company’s stock worth $11,977,000 after purchasing an additional 2,275,000 shares during the period. 72.83% of the stock is currently owned by institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.